
Ose Pharma gets clinical milestone for IL7R antagonist
Under the deal inked in 2016, immuno-oncology and autoimmune specialist Ose Immunotherapeutics develops its IL-7-receptor...

Forbion leads €40m financing in Inflazome Ltd
Inflazome said it will use the proceeds to develop its small molecule NLRP3 inflammasome inhibitor to clinical proof-of-concept in several chronic...

Staten Biotechnology in $430m deal with Novo Nordisk
Under the agreement, Dutch Staten Biotechnology B.V. and Novo Nordisk A/S will collaborate to co-develop Staten's preclinical dyslipidemia...

Sugar replacement slows cancer growth
Feeding mannose either alone or alongside chemotherapy through a feeding tube three times a week and continuously via their drinking water was...

MEPs back €120bn budget for Horizon Europe
While the EU will miss its target to raise total public and private R&D spending in the EU to 3% of GDP by 2020 - in 2017 the EU average was...

Boehringer and Epizyme enter US$300m deal
According to BI, more than half of cancers can stem from functional errors in epigenetic modification, which diagnostically characterise the patient...